Recent evidence highlights GLP‐1R agonists as potent agents in reducing ICP, significantly more effectively than traditional treatments for intracranial hypertension, such as acetazolamide or topiramate, and consistent with our findings, this effect is unrelated to weight loss.22, 23. The gene discussed is GLP1R; the disease is intracranial hypertension.